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Abstract
Tests were performed on the in¯uence of polymer coating ®lms on the rates and the extents of in vitro and in vivo liberation of theophylline
from pellets. Uncoated and coated pellets were used in the experiments. The coating material was Eudragit L; The ®lm thickness was varied.
The in vivo liberation of theophylline was studied in rabbits. The serum level of the released drug measured with a TDX Analyser. No
appreciable difference was observed between the uncoated and the coated pellets as concern the maximum release data, but a signi®cant shift
was found in tmax for Eudragit L coated pellets. q 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Solid dosage forms play an important role in pharmaceu-
tical production. Studies aimed at a better understanding of
factors acting on pellets and pellet-based tablets are there-
fore of primary concern [1,2].
Film-coated solid dosage forms, e.g. pellets and tablets,
are currently of increasing importance. An appropriate coat-
ing ¯uid applied to a pellet surface produces a macromole-
cular ®lm coat, the properties of which will in¯uence the
pellet parameters and the liberation of drug from the pellets
and from the tablets manufactured from them [3±7]. The
thickness of this ®lm in¯uences the rate of dissolution of
the drug. For this reason, the ®lm thickness is an important
factor.
Dissolution tests are performed under in vitro conditions,
but to optimize a dosage form the in vivo investigations are
also necessary [8±12].
In this work, an enteric polymer was studied. Theophyl-
line was the chosen drug. The serum theophylline levels
comprise an individual monitoring tool in theophylline
dosing. The dosing of theophylline is complicated by the
extensive variation in bioavailability among patients.
Theophylline has a relatively low therapeutic index.
Appropriate dosing is therefore critical, and should be
based on patient response and tolerance, pulmonary func-
tion, and serum theophylline concentrations [13]. In
general, therapeutic serum theophylline concentrations
range from 5 to 15 mg/ml. Toxicity usually appears at
concentrations above 20 mg/ml. Peak theophylline levels
are good correlated with ef®cacy and toxicity [14,15]. The
recommended time to obtain a peak serum theophylline
concentration level after an initial intravenous aminophyl-
line dose is 30 min after completion of the loading dose
[16]. For an orally administered theophylline solution or
uncoated tablet and extended-release theophylline prepara-
tions, 1±2 h and 3±12 h after the initial dose, respectively,
are recommended [13,14]. The manufacturers of once-a-
day theophylline preparations recommend that peak theo-
phylline serum concentration levels should be measured at
8±12 h after a dose of theophylline, respectively. Trough
levels may be obtained just prior to the next dose of theo-
phylline, but these levels do not generally provide any
clinically relevant information. On each occasion, blood
samples should be obtained during the same dosing inter-
val, in order to minimize the circadian variation in theo-
phylline absorption.
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2. Experimental
2.1. Materials
2.1.1. Core
For the Theophylline pellets, the following materials
were used: Theophylline (Theophyllinum, Ph. Eur. 3) 200
g, mannitol (Mannitum, Ph. Eur. 3) 300 g, Vitacel A 300w
(Rettenmaier & SoÈhne GmbH & Co., Ellwangen-Holz-
muÈhle, Germany) 500 g, Kollidon VA 64w (BASF Aktien-
gesellschaft GmbH, Ludwigshafen, Germany) 57 g, and
saccharose (Saccharosum, Ph. Eur. 3) 450 g, corn starch
(Ph. Eur. 3) 170 g, silica, colloidal anhydrous (Ph. Eur. 3)
11 g.
2.1.2. Coating material
Eudragit L 100-55w (RoÈhm-Pharma GmbH Chemische
Fabrik, Darmstadt, Germany) An anionic copolymer of
methacrylic acid and acrylate with an average molecular
mass of 250 000. It is a ®ne white powder that also contains
sodium dodecylsulfate (0.7%) and polysorbate 80 (2.3%).
Eudragit is soluble in organic solvents. In water, it does not
dissolve, but is dispersed [17]. The ®lm formed from a water
dispersion of Eudragit L 100-55 starts to dissolve at pH 5.5,
which makes it suitable for enteric coatings.
2.2. Methods
2.2.1. Preparation of pellets
The core material was placed in the working space of a
centrifugal granulator (Freund CF-360, Japan). Pelletizing
was performed at a rotor speed of 200 rev./min, with a
granulating ¯uid feed rate of 20 rev./min ( 20 ml/min),
and an atomizing air pressure of 4,6 atm, the build-up
powder being introduced discontinuously, at 20 rev./min,
and at an inlet and outlet air temperature of 408C.
2.2.2. Coating process
A Strea-1 ¯uid bed apparatus was used with a Wurster
container (Niro-Aeromatic, Bubendorf, Switzerland). Coat-
ing was performed at an atomizing pressure of 2 bar, a blow-
out pressure of 4.2 bar, a coating ¯uid rate of 5 ml/min, and
a drying temperature of 408C.
2.2.3. In vitro dissolution of the active agent
The rotating basket method with half change [18] was
used. The test was started with arti®cial gastric ¯uid, half
of which was changed to intestinal ¯uid every hour. In this
way, the pH changes were similar to those seen in the diges-
tive tract.
2.2.3.1. Test conditions. Apparatus: Pharma Test PTW 2
with six measuring sites and microprocessor control
(Pharma Test GmbH, Germany). Rotation speed: 50 rev./
min. Temperature: 37 ^ 18C. Dissolution medium volume:
900 ml. Sampling time: 1, 2, 3, 4, 5, 6 and 7 h.
Measurement: with a UV spectrophotometer (Spektromom
195D, MOM, Hungary) at 268 nm for pH 1.18±1.91, at
270 nm for pH 6.24±6.92, and at 271 nm for pH 7.22±
7.51.
Computerized data processing: SPSS for Windows 6.1.2.
Copyright (C) SPSS Inc., USA
2.2.4. In vivo experiments
New-Zealand white rabbits (2500±3000 g) were treated
orally with gelatine capsules containing 0.2 g theophylline
pellets (dosage:10 mg/kg). The animals were fasted for 12 h
before the experiments. The capsules were introduced
directly into the oesophagus and washed in with 5 ml of
distilled water in order to avoid possible damage caused
by chewing. Blood samples were collected from ear veins
1, 2, 3, 4, 5, 6, 8, 12 and 24 h after the oral administration.
The samples were centrifuged at 14 500 rev./min with a
TDX centrifuge (Abbott Laboratories, Germany) and plas-
mas were stored at 2208C for further analytical determina-
tion.
The centrifuged plasma samples were measured with a
TDX Analyzer (Automated Fluorescence Polarization
Analyzer No. 9520-04, Abbott Laboratories, Germany).
Minimum sample volume required in sample well: 50 ml.
For validation of the assay, control samples containing
human blood components were used.
3. Results and discussion
The disintegration of the uncoated pellets in the in vitro
test was complete in 5 min, which is in accordance with the
release of 35% of the agent in the ®rst 5 min (Fig. 1). From
the 5th min on, the dissolution curve declined. The dissolu-
tion rate became lower and the amount of agent liberated
progressively fell off up to the end of the investigation. The
linear model re¯ects the dissolution of the active agent
(P , 0:05; r  0:953).
For the coated pellets, the dissolution pro®les (Fig. 2) are
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Fig. 1. Dissolution of theophylline from uncoated pellet.
sigmoidal in both cases. Theophylline initially dissolves at a
low rate, predominantly by diffusion through the coating
and its possible discontinuities. Between 2 and 3 h,
however, when the pH of the dissolution medium reaches
the level critical for the coating (pH 5.5), the ®lm starts to
dissolve, thereby increasing the diffusion. Such a curve is
also typical for retard forms, but the adequate plasma level
will develop later, after the passage of the pellets into the
intestine. The mathematical evaluation of the dissolution
process was studied according to Rosin-Rammler-Sper-
ling-Bennett-Weibull (RRSBW) distribution and the char-
acteristical dissolution time (t63.2%) was determined [19].
Signi®cant difference was found; t63.2% was 99.04 min
(P , 0:05, r  0:9930) in the case of 64 mm in ®lm thick-
ness and it was 171.74 min (P , 0:05, r  0:9610) at the 85
mm in thickness.
The plasma level of theophylline released from uncov-
ered pellets rose quickly and the maximum concentration
(14.36 mg/l) (Fig. 3) was reached by 2 h after administra-
tion. The changes in concentration between 2 and 4 h was
not signi®cant. After 3 h, the theophylline plasma level
decreased. There was a major fall in plasma concentration
between 4 and 12 h. The rate of decline moderated between
12 and 24 h.
The blood concentration of theophylline released from
pellets covered with Eudragit L (64 mm) reached the maxi-
mum value (11.22 mg/l) at 6 h (Table 1). The decrease in
theophylline concentration occured at a lower rate than that
for the uncoated pellets.
Similarly as for Eudragit L (64 mm), the theophylline
released from pellets coated with Eudragit L (85 mm)
reached its maximum concentration (10.24 mg/l) at 6 h
and the decrease in theophylline concentration was also
similar to that for Eudragit L (64 mm). The AUC values
were calculated (Table 1) and mathematical evaluation
(paired t-test) was performed. The difference in the AUC
values was not signi®cant.
Finally, it can be concluded, that in the in vivo studies, the
dissolution can be characterized by the value of the maxi-
mum concentration (cmax) and the time necessary to reach
this (tmax). There was no great difference in the maximum
values (all the pellets gave cmax . 10 mg/l) between the
uncoated and the Eudragit L-coated pellets, but a signi®cant
shift in tmax was found for both Eudragit-coated pellets
(P , 0:05, r  0:9992). The difference was 4 h as compared
with the uncoated preparation. This result exhibits a rela-
tionship to the difference between the in vitro dissolutions (3
h), which con®rms the reliability of the in vitro dissolution
method. The slower decreases in theophylline concentration
in the cases of the Eudragit L (64 mm) and Eudragit L (85
mm) ®lms demonstrate the effectiveness of the enteric coat-
ing process.
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